Welcome to Enabled Therapeutics, formerly known as Mercaptor. We are excited to share that all information on our website including our Capton intellectual property and approach is now managed by the founders of Enabled Therapeutics. This marks an exciting new phase in the development of Captons, and we look forward to advancing therapeutic solutions. All historical news below refers to Mercaptor, our former name.
Enabled Therapeutics Announces Board Appointment of Jivan Achreja as It Introduces a New Era in Precision Neurology
Enabled Therapeutics strengthens leadership team as it redefines neurology with on-site drug synthesis and precision brain therapeutics.
Enabled Therapeutics Gains FDA Alignment for CPT-021: A First-of-Its-Kind Targeted Therapy for Alzheimer’s
Enabled Therapeutics Gains FDA Alignment for CPT-021: A First-of-Its-Kind Targeted Therapy for Alzheimer’s
Mercaptor Introduces Powerful CAPTON™️ Platform for Precision Neurology
New Technology Addresses Brain Trauma Including Alzheimer’s, TBI, and Epilepsy SAN FRANCISCO, Jan. 5, 2024 /PRNewswire-PRWeb/ — Mercaptor Inc, a privately held pharmaceutical company, today announced a breakthrough
Update on COVID-19: Its Treatment and its Cure, Horasis Global Meeting 2021
Mercaptor Discoveries advances drug candidate to treat brain inflammation in people with long COVID
https://www.prnewswire.com/news-releases/mercaptor-discoveries-advances-drug-candidate-to-treat-brain-inflammation-in-people-with-long-covid-301318107.html Mercaptor Discoveries (Mercaptor) today advanced their therapeutic candidate to treat brain-inflammation found in patients with long COVID, also known as post-acute sequelae of COVID-19. Long
Mercaptor Discoveries Uses its Proprietary Neurotherapeutic Platform to Develop Treatment for COVID-19
NOVATO, Calif., May 18, 2020 /PRNewswire/ — Mercaptor Discoveries (Mercaptor), a platform company with preclinical programs in epilepsy and TBI, today announced that it is pivoting its